Journal article

Human Neonatal Rotavirus Vaccine (RV3-BB) Produces Vaccine Take Irrespective of Histo-Blood Group Antigen Status

Karen Boniface, Sean G Byars, Daniel Cowley, Carl D Kirkwood, Julie E Bines

JOURNAL OF INFECTIOUS DISEASES | OXFORD UNIV PRESS INC | Published : 2020

Abstract

BACKGROUND: VP4 [P] genotype binding specificities of rotaviruses and differential expression of histo-blood group antigens (HBGAs) between populations may contribute to reduced efficacy against severe rotavirus disease. P[6]-based rotavirus vaccines could broaden protection in such settings, particularly in Africa, where the Lewis-negative phenotype and P[6] rotavirus strains are common. METHODS: The association between HBGA status and G3P[6] rotavirus vaccine (RV3-BB) take was investigated in a phase 2A study of RV3-BB vaccine involving 46 individuals in Dunedin, New Zealand, during 2012-2014. FUT2 and FUT3 genotypes were determined from DNA extracted from stool specimens, and frequencies ..

View full abstract

Grants

Awarded by Australian National Health and Medical Research Council


Awarded by New Zealand Health Research Council International Investment Opportunities Fund Trans-Tasman Clinical Trials Collaborative Initiative


Funding Acknowledgements

This work was supported by the Australian National Health and Medical Research Council (project grant ID491239), the New Zealand Health Research Council International Investment Opportunities Fund Trans-Tasman Clinical Trials Collaborative Initiative (08_T02), and the Victorian Government's Operational Infrastructure Support Program.